Literature DB >> 477637

The use of althesin in drug-resistent status epilepticus.

C Munari, D Casaroli, G Matteuzzi, L Pacifico.   

Abstract

The properties of Althesin (anticonvulsant activity, depression of oxygen consumption, lowering of ICP, rapid excretion) led us to use this steroid combination to treat 11 patients in status epilepticus resistant to the standard drugs (benzodiazepines and barbiturates). The administration of Althesin by slow intravenous injection was ineffective in 2 of the 3 patients thus treated. The doses used (2--10 ml) were probably too small. One only administration of a 10% solution of Althesin in 10% fructose by intravenous drip (the rate was calculated so as to obtain the burst suppression stage at the EEG) stopped status epilepticus in 7 of the 9 patients thus treated. In this group the doses used varied from 25 to 50 ml. The 2 patients in whom it was necessary to repeat Althesin administration and combine it with other drugs had both been operated on for severe brain injuries involving marked cerebral edema. In spite of the very small number of cases, the definitive arrest of status epilepticus obtained in 8 out of 11 patients first treated with other drugs is encouraging: Althesin probably may be regarded as an adjunct in the treatment of status epilepticus.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 477637     DOI: 10.1111/j.1528-1157.1979.tb04829.x

Source DB:  PubMed          Journal:  Epilepsia        ISSN: 0013-9580            Impact factor:   5.864


  4 in total

Review 1.  Identification and characterization of a pregnane steroid recognition site that is functionally coupled to an expressed GABAA receptor.

Authors:  N C Lan; M B Bolger; K W Gee
Journal:  Neurochem Res       Date:  1991-03       Impact factor: 3.996

Review 2.  Generalized convulsive status epilepticus: pathophysiology and treatment.

Authors:  F B Scholtes; W O Renier; H Meinardi
Journal:  Pharm World Sci       Date:  1993-02-19

3.  Realising the therapeutic potential of neuroactive steroid modulators of the GABAA receptor.

Authors:  Delia Belelli; Derk Hogenkamp; Kelvin W Gee; Jeremy J Lambert
Journal:  Neurobiol Stress       Date:  2019-12-23

4.  A Phase 1c Trial Comparing the Efficacy and Safety of a New Aqueous Formulation of Alphaxalone with Propofol.

Authors:  John Monagle; Lyndon Siu; Jodie Worrell; Colin S Goodchild; Juliet M Serrao
Journal:  Anesth Analg       Date:  2015-10       Impact factor: 6.627

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.